PURPOSE: To determine whether cancer risks for carriers and noncarriers from families with a mismatch repair (MMR) gene mutation are increased above the risks of the general population. PATIENTS AND METHODS: We prospectively followed a cohort of 446 unaffected carriers of an MMR gene mutation (MLH1, n = 161; MSH2, n = 222; MSH6, n = 47; and PMS2, n = 16) and 1,029 their unaffected relatives who did not carry a mutation every 5 years at recruitment centers of the Colon Cancer Family Registry. For comparison of cancer risk with the general population, we estimated country-, age-, and sex-specific standardized incidence ratios (SIRs) of cancer for carriers and noncarriers. RESULTS: Over a median follow-up of 5 years, mutation carriers had an increased risk of colorectal cancer (CRC; SIR, 20.48; 95% CI, 11.71 to 33.27; P < .001), endometrial cancer (SIR, 30.62; 95% CI, 11.24 to 66.64; P < .001), ovarian cancer (SIR, 18.81; 95% CI, 3.88 to 54.95; P < .001), renal cancer (SIR, 11.22; 95% CI, 2.31 to 32.79; P < .001), pancreatic cancer (SIR, 10.68; 95% CI, 2.68 to 47.70; P = .001), gastric cancer (SIR, 9.78; 95% CI, 1.18 to 35.30; P = .009), urinary bladder cancer (SIR, 9.51; 95% CI, 1.15 to 34.37; P = .009), and female breast cancer (SIR, 3.95; 95% CI, 1.59 to 8.13; P = .001). We found no evidence of their noncarrier relatives having an increased risk of any cancer, including CRC (SIR, 1.02; 95% CI, 0.33 to 2.39; P = .97). CONCLUSION: We confirmed that carriers of an MMR gene mutation were at increased risk of a wide variety of cancers, including some cancers not previously recognized as being a result of MMR mutations, and found no evidence of an increased risk of cancer for their noncarrier relatives.
PURPOSE: To determine whether cancer risks for carriers and noncarriers from families with a mismatch repair (MMR) gene mutation are increased above the risks of the general population. PATIENTS AND METHODS: We prospectively followed a cohort of 446 unaffected carriers of an MMR gene mutation (MLH1, n = 161; MSH2, n = 222; MSH6, n = 47; and PMS2, n = 16) and 1,029 their unaffected relatives who did not carry a mutation every 5 years at recruitment centers of the Colon Cancer Family Registry. For comparison of cancer risk with the general population, we estimated country-, age-, and sex-specific standardized incidence ratios (SIRs) of cancer for carriers and noncarriers. RESULTS: Over a median follow-up of 5 years, mutation carriers had an increased risk of colorectal cancer (CRC; SIR, 20.48; 95% CI, 11.71 to 33.27; P < .001), endometrial cancer (SIR, 30.62; 95% CI, 11.24 to 66.64; P < .001), ovarian cancer (SIR, 18.81; 95% CI, 3.88 to 54.95; P < .001), renal cancer (SIR, 11.22; 95% CI, 2.31 to 32.79; P < .001), pancreatic cancer (SIR, 10.68; 95% CI, 2.68 to 47.70; P = .001), gastric cancer (SIR, 9.78; 95% CI, 1.18 to 35.30; P = .009), urinary bladder cancer (SIR, 9.51; 95% CI, 1.15 to 34.37; P = .009), and female breast cancer (SIR, 3.95; 95% CI, 1.59 to 8.13; P = .001). We found no evidence of their noncarrier relatives having an increased risk of any cancer, including CRC (SIR, 1.02; 95% CI, 0.33 to 2.39; P = .97). CONCLUSION: We confirmed that carriers of an MMR gene mutation were at increased risk of a wide variety of cancers, including some cancers not previously recognized as being a result of MMR mutations, and found no evidence of an increased risk of cancer for their noncarrier relatives.
Authors: R J Scott; M McPhillips; C J Meldrum; P E Fitzgerald; K Adams; A D Spigelman; D du Sart; K Tucker; J Kirk Journal: Am J Hum Genet Date: 2000-12-07 Impact factor: 11.025
Authors: H T Lynch; P Watson; M Kriegler; J F Lynch; S J Lanspa; J Marcus; T Smyrk; R J Fitzgibbons; G Cristofaro Journal: Dis Colon Rectum Date: 1988-05 Impact factor: 4.585
Authors: H J Järvinen; M Aarnio; H Mustonen; K Aktan-Collan; L A Aaltonen; P Peltomäki; A De La Chapelle; J P Mecklin Journal: Gastroenterology Date: 2000-05 Impact factor: 22.682
Authors: H F Vasen; A Stormorken; F H Menko; F M Nagengast; J H Kleibeuker; G Griffioen; B G Taal; P Moller; J T Wijnen Journal: J Clin Oncol Date: 2001-10-15 Impact factor: 44.544
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Marcia Irene Canto; Michael Goggins; Charles J Yeo; Constance Griffin; Jennifer E Axilbund; Kieran Brune; Syed Z Ali; Sanjay Jagannath; Gloria M Petersen; Elliot K Fishman; Steven Piantadosi; Francis M Giardiello; Ralph H Hruban Journal: Clin Gastroenterol Hepatol Date: 2004-07 Impact factor: 11.382
Authors: M G Dunlop; S M Farrington; I Nicholl; L Aaltonen; G Petersen; M Porteous; A Carothers Journal: Br J Cancer Date: 2000-12 Impact factor: 7.640
Authors: L H Katz; A M Burton-Chase; S Advani; B Fellman; K M Polivka; Y Yuan; P M Lynch; S K Peterson Journal: Clin Genet Date: 2015-09-14 Impact factor: 4.438
Authors: Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle Journal: J Clin Oncol Date: 2013-12-09 Impact factor: 44.544
Authors: Aung Ko Win; Noralane M Lindor; Ingrid Winship; Katherine M Tucker; Daniel D Buchanan; Joanne P Young; Christophe Rosty; Barbara Leggett; Graham G Giles; Jack Goldblatt; Finlay A Macrae; Susan Parry; Matthew F Kalady; John A Baron; Dennis J Ahnen; Loic Le Marchand; Steven Gallinger; Robert W Haile; Polly A Newcomb; John L Hopper; Mark A Jenkins Journal: J Natl Cancer Inst Date: 2013-02-05 Impact factor: 13.506
Authors: James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins Journal: Hum Mutat Date: 2013-03 Impact factor: 4.878
Authors: Victoria M Raymond; Bhramar Mukherjee; Fei Wang; Shu-Chen Huang; Elena M Stoffel; Fay Kastrinos; Sapna Syngal; Kathleen A Cooney; Stephen B Gruber Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544